Y0000366
Isradipine
European Pharmacopoeia (EP) Reference Standard
동의어(들):
4-(4-Benzofurazanyl)-1,-4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester
로그인조직 및 계약 가격 보기
모든 사진(1)
크기 선택
보기 변경
125 MG
₩186,963
About This Item
실험식(Hill 표기법):
C19H21N3O5
CAS Number:
Molecular Weight:
371.39
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24
추천 제품
Grade
pharmaceutical primary standard
API family
isradipine
제조업체/상표
EDQM
응용 분야
pharmaceutical (small molecule)
형식
neat
저장 온도
2-8°C
SMILES string
COC(=O)C1=C(C)NC(C)=C(C1c2cccc3nonc23)C(=O)OC(C)C
InChI
1S/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3
InChI key
HMJIYCCIJYRONP-UHFFFAOYSA-N
유전자 정보
human ... CACNA1C(775) , CACNA1D(776) , CACNA1F(778) , CACNA1S(779)
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Isradipine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
생화학적/생리학적 작용
L-type calcium channel blocker (also referred to as dihydropyridine-type calcium channel blocker); antihypertensive.
L-type calcium channel blocker; antihypertensive.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
관련 제품
제품 번호
설명
가격
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
J Marty
Acta anaesthesiologica Scandinavica. Supplementum, 99, 53-55 (1993-01-01)
The traditional therapy of perioperative hypertension is now being challenged by the availability of new agents. Vasodilator therapy should be the first-line choice, although dihydropyridine calcium antagonists, particularly isradipine, appear to be suitable in this setting because of their pharmacological
D Panuccio et al.
La Clinica terapeutica, 146(11), 729-736 (1995-11-01)
The aim of the present study was to evaluate efficacy on blood pressure values and metabolic tolerability of Isradipine, which was given to 15 mild hypertensive non diabetic subjects (average age 63.8 +/- 10.9 years), at the dosage of 5
W H Frishman
Journal of clinical pharmacology, 34(12), 1164-1172 (1994-12-01)
In the treatment of hypertension in renally impaired patients, normalization of blood pressure alone may not be sufficient to prevent significant morbidity to the kidneys. Treatment must reduce pressure in the renal vasculature, otherwise glomerular filtration rate and renal plasma
R P Hof et al.
American journal of hypertension, 4(2 Pt 2), 107S-113S (1991-02-01)
In the context of atherosclerosis, calcium antagonists should be evaluated from two points of view: their hemodynamic action on the atherosclerotic cardiovascular system, and their preventive action on atherosclerosis. Contraction of atherosclerotic vessels in response to vasoconstrictors, especially serotonin and
H Sinzinger et al.
Journal of cardiovascular pharmacology, 19 Suppl 3, S29-S31 (1992-01-01)
Isradipine, a calcium antagonist of the dihydropyridine type, shows antiatherosclerotic actions that interfere with all three main mechanisms of atherosclerosis. These actions are mediated by the release of prostaglandin I2 and endothelium-derived relaxing factor, and the subsequent elevation of intracellular
활성 필터
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.
